NASDAQ:INVA - Innoviva Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $14.19 -0.09 (-0.63 %) (As of 07/20/2018 04:00 PM ET)Previous Close$14.19Today's Range$14.16 - $14.3952-Week Range$11.47 - $17.99Volume584,956 shsAverage Volume772,671 shsMarket Capitalization$1.45 billionP/E Ratio12.13Dividend YieldN/ABeta2.19 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California. Receive INVA News and Ratings via Email Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:INVA CUSIP88338T10 Webwww.inva.com Phone650-238-9600 Debt Debt-to-Equity Ratio-2.28 Current Ratio27.89 Quick Ratio27.89 Price-To-Earnings Trailing P/E Ratio12.13 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$217.22 million Price / Sales6.65 Cash Flow$1.4905 per share Price / Cash9.52 Book Value($2.38) per share Price / Book-5.96 Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$134.14 million Net Margins64.11% Return on Equity-63.57% Return on Assets44.05% Miscellaneous Employees12 Outstanding Shares101,820,000Market Cap$1,454.05 Innoviva (NASDAQ:INVA) Frequently Asked Questions What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." How were Innoviva's earnings last quarter? Innoviva Inc (NASDAQ:INVA) released its earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by $0.23. The biotechnology company earned $52.40 million during the quarter, compared to analyst estimates of $71.84 million. Innoviva had a net margin of 64.11% and a negative return on equity of 63.57%. Innoviva's revenue was up 29.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.19 EPS. View Innoviva's Earnings History. When is Innoviva's next earnings date? Innoviva is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Innoviva. What price target have analysts set for INVA? 6 Wall Street analysts have issued twelve-month target prices for Innoviva's stock. Their forecasts range from $8.00 to $16.00. On average, they anticipate Innoviva's share price to reach $13.20 in the next twelve months. This suggests that the stock has a possible downside of 7.0%. View Analyst Ratings for Innoviva. What is the consensus analysts' recommendation for Innoviva? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Innoviva's key competitors? Some companies that are related to Innoviva include Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and Array Biopharma (ARRY). Who are Innoviva's key executives? Innoviva's management team includes the folowing people: Mr. Eric d'Esparbes, Interim Principal Exec. Officer, Sr. VP & CFO (Age 50)Dr. Theodore J. Witek Jr., Sr. VP & Chief Scientific Officer (Age 60)Mr. George B. Abercrombie M.B.A., R.Ph., RPh, MBA, Sr. VP & Chief Commercial Officer (Age 63)Mr. Geoffrey Hulme, Interim Principal Exec. OfficerMr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP Has Innoviva been receiving favorable news coverage? News stories about INVA stock have been trending somewhat negative recently, according to Accern. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Innoviva earned a daily sentiment score of 0.00 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. Who are Innoviva's major shareholders? Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional investors include James Investment Research Inc. (0.20%), Creative Planning (0.04%), Campbell & CO Investment Adviser LLC (0.04%), Municipal Employees Retirement System of Michigan (0.03%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva. Which major investors are selling Innoviva stock? INVA stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva. Which major investors are buying Innoviva stock? INVA stock was acquired by a variety of institutional investors in the last quarter, including James Investment Research Inc., Campbell & CO Investment Adviser LLC, Creative Planning and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Innoviva. How do I buy shares of Innoviva? Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $14.19. How big of a company is Innoviva? Innoviva has a market capitalization of $1.45 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe. How can I contact Innoviva? Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected] MarketBeat Community Rating for Innoviva (NASDAQ INVA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 209 (Vote Outperform)Underperform Votes: 249 (Vote Underperform)Total Votes: 458MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?